INNATE PHARMA SA-SPONS ADR (IPHA) Stock News

USA - Nasdaq - NASDAQ:IPHA - US45781K2042 - ADR

1.86 USD

+0.01 (+0.54%)

Last: 12/12/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IPHA Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Innate Pharma SA

Innate Pharma Releases Its 2026 Financial Calendar

16 days ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

a month ago - By: Innate Pharma SA

Innate Pharma to Present at Jefferies Global Healthcare Conference

a month ago - By: Innate Pharma SA

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

a month ago - By: Stocktwits - Mentions: CNCR

News Image

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

3 months ago - By: Benzinga - Mentions: CBRL GIS STC MANU ...

Earnings Scheduled For September 17, 2025

a month ago - By: Benzinga - Mentions: ZYXI OM SNES SLNO ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

a month ago - By: Innate Pharma SA

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

a month ago - By: Zacks Investment Research

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

a month ago - By: Innate Pharma SA

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

2 months ago - By: Innate Pharma SA

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

3 months ago - By: Innate Pharma SA

Innate Pharma Reports First Half 2025 Business Update and Financial Results

3 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

3 months ago - By: Innate Pharma SA

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

3 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

4 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025

5 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

5 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

6 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

6 months ago - By: Innate Pharma SA

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

7 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

7 months ago - By: Innate Pharma SA

Outcome of Innate Pharma’s 2025 Annual General Meeting

7 months ago - By: Innate Pharma SA

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

7 months ago - By: Innate Pharma SA

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

7 months ago - By: Innate Pharma SA

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

7 months ago - By: Innate Pharma SA

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

7 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

7 months ago - By: Innate Pharma SA

Innate Pharma announces conference call and webcast for Q1 2025 business update

8 months ago - By: Innate Pharma SA

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

8 months ago - By: Innate Pharma SA

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting